CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

BMS, says Kaiser, is tripling down on BCMA across different modalities. Multiple avenues for therapy Among these novel modalities, chimeric antigen receptor (CAR) T cells have the longest history ...

Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

There was also a 2.5-fold increase over DVd on the proportion of patients with minimal residual disease (MRD ... at earlier-line use. Two BCMA-directed CAR-T therapies have been approved ...

Anito-cel is a B-cell maturation antigen chimeric antigen receptor (BCMA CAR) T-cell therapy ... overall survival, minimal residual disease negativity, and safety will be the secondary endpoints.

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...